Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties

Moghimi, S. Moein; Szebeni, János

doi:10.1016/s0163-7827(03)00033-x

Cited by 1,083 publications

(741 citation statements)

References 64 publications

Supporting

Mentioning

714

Contrasting

Unclassified

Order By: Relevance

“…We then synthesized PEG-coated-NPs (referred to as PEGNPs) to avoid rapid clearance from blood and to increase circulation time, because the use of PEG capping has already been shown to increase the circulation time of several colloidal systems (20). Neutral PEG-NPs covered by a PEG shield were able to circulate longer, as assessed by a diffuse signal throughout the mouse body that lasted during all of the acquisition time ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Nanoprobes with near-infrared persistent luminescence for in vivo imaging

Chermont

Chanéac

Séguin

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

736

489

View full text Add to dashboard Cite

Fluorescence is increasingly used for in vivo imaging and has provided remarkable results. Yet this technique presents several limitations, especially due to tissue autofluorescence under external illumination and weak tissue penetration of low wavelength excitation light. We have developed an alternative optical imaging technique by using persistent luminescent nanoparticles suitable for small animal imaging. These nanoparticles can be excited before injection, and their in vivo distribution can be followed in real-time for more than 1 h without the need for any external illumination source. Chemical modification of the nanoparticles' surface led to lung or liver targeting or to long-lasting blood circulation. Tumor mass could also be identified on a mouse model. biodistribution ͉ in vivo optical imaging ͉ nanoparticles ͉ phosphorescent nanoparticles

show abstract

Section: Resultsmentioning

confidence: 99%

Nanoprobes with near-infrared persistent luminescence for in vivo imaging

Chermont

Chanéac

Séguin

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

736

489

View full text Add to dashboard Cite

show abstract

“…For example, studies often fail to perfuse animals before tissue examination [45][46][47][48][49], making it difficult to discriminate between NPs in the bloodstream and NPs adherent to the endothelium or NPs that have gained access to the organ parenchyma. In non-perfused animals after intravenous (IV) NP administration, the high intravenous NP content in organs with large blood volumes makes assessment of biodistribution extremely difficult by most modalities and the accurate evaluation of NP interactions with specific cells in the tissue virtually impossible (D.R.…”

Section: Np Administration Route and Organ Localizationmentioning

confidence: 99%

Harnessing Nanoparticles for Immune Modulation

Getts¹,

Shea²,

Miller³

et al. 2016

Trends in Immunology

View full text Add to dashboard Cite

Recent approaches using nanoparticles engineered for immune regulation have yielded promising results in preclinical models of disease. The number of nanoparticle therapies is growing, fueled by innovations in nanotechnology and advances in understanding of the underlying pathogenesis of immune-mediated diseases. In particular, recent mechanistic insight into the ways in which nanoparticles interact with the mononuclear phagocyte system and impact its function during homeostasis and inflammation have highlighted the potential of nanoparticle-based therapies for controlling severe inflammation while concurrently restoring peripheral immune tolerance in autoimmune disease. Here we review recent advances in nanoparticle-based approaches aimed at immune-modulation, and discuss these in the context of concepts in polymeric nanoparticle development, including particle modification, delivery and the factors associated with successful clinical deployment.

show abstract

“…66,68 PEG surfaces in brush-like and intermediate configurations reduced phagocytosis and complement activation, whereas PEG surfaces in mushroom-like configuration were potent complement activators and favored phagocytosis. 32,47,69,70 Based on the Alexander-de Gennes model, the distance between PEG chains should be around 1 nm to repel small globular proteins (approximately 2 nm radius) and 1.5 nm to repel large ones (6-8 nm). 32 Due to the large choice in the PLA or PEG molecular weights available, the conformation of PEG blocks at the PEG-PLA nanoparticle surface is a complex issue to be addressed.…”

Section: Nanoparticle Preparationmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties

Cited by 1,083 publications

References 64 publications

Nanoprobes with near-infrared persistent luminescence for in vivo imaging

Nanoprobes with near-infrared persistent luminescence for in vivo imaging

Harnessing Nanoparticles for Immune Modulation

Drug transport to brain with targeted nanoparticles

Contact Info

Product

Resources

About